Clinical Trial

Improving Functional Outcomes and Quality of Life in Patients With Rectal Cancer After Surgery With Intensified Follow-up & Surveillance

Study acronym: iRECOVER
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The goal of this clinical study is to gain further insights into the treatment of patients with Low Anterior Resection Syndrome (LARS) symptoms after rectal resection. The main question is: Can LARS symptoms and quality of life be improved by implementing an intensified follow-up program? Researchers will compare the results of the intervention group with the results of a control group in which patients do not receive an intensified follow-up program to determine whether the intervention works. Participants will undergo an intensified follow-up program which consists of several follow-up visits and medical treatment, pelvic floor muscle training and gynaecological and urological co-treatment in case of LARS symptoms and urinary or sexual complaints.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-04-17; most recent amendment 2026-04-30.
Status change: Not Yet Recruiting → Recruiting 2026-04-30
Trial Details
NCT Number NCT06936774
Lead Sponsor University Hospital, Basel, Switzerland
Collaborators: St. Claraspital AG, Clarunis - Universitäres Bauchzentrum Basel
Conditions LARS - Low Anterior Resection Syndrome, Rectal Cancer Surgery, Rectal Cancer, Quality of Life (QOL)
Enrollment 140 participants
Start Date 2025-12-01
Primary Completion 2028-05-01 (estimated)
Study Completion 2028-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-06